The direct oral anticoagulant (DOAC) edoxaban is superior to warfarin for mitigating stroke risk in Latin American patients with atrial fibrillation (AFib), according to results of the ENGAGE AF-TIMI trial.

Optimal candidates for a switch from vitamin K antagonists like warfarin to direct oral anticoagulants (DOACs) have long been identified by a single statistic—time-in-therapeutic range—but a recent Danish analysis of anticoagulants in atrial fibrillation patients suggests the marker might be less insightful than previously thought.

French pharmaceutical company Servier has partnered with Bioserenity to launch a “smart T-shirt” they’re calling the Cardioskin—a wearable innovation that would allow heart patients to monitor their cardiac rhythm throughout the day, the Daily Mail has reported.

Scientists hope personalized data from patients experiencing irregular heartbeats will help improve accuracy in heart ablation procedures. The 3D simulations of 21 patients allow physicians to locate arrhythmia by “poking” the simulated heart with small electrical signals in various locations.

The Apple Watch Series 4—the device’s first major update since its introduction to the market three years ago—will feature an electrocardiogram in addition to its existing heart rate monitor, the Verge reported this week.

The majority of firefighters who die from cardiac arrest while on duty have underlying coronary heart disease (CHD) and an enlarged heart, including left ventricular hypertrophy, according to a study of autopsy data published in the Journal of the American Heart Association.

A prevalence of left atrial fibrosis in endurance athletes could explain their increased risk for arrhythmias like atrial fibrillation (AFib), according to data presented this week at the European Society of Cardiology (ESC) Congress in Munich.

Combining oral anticoagulants with antiplatelet therapy in atrial fibrillation (AFib) patients could be more than just overkill, University of Edinburgh researchers reported at the European Society of Cardiology’s annual meeting this month. It could be dangerous, increasing the risk for all-cause death, stroke and major bleeding events in those without an indication for dual treatment.